Pay in 4 interest-free payments of $25.00 Learn more
Ships within 48 hours · Estimated delivery Aug 6 - Aug 11
ROC-325 exhibited superior in vitro anticancer effects compared with the existing autophagy inhibitor hydroxychloroquine (HCQ) in 12 different cancer cell lines with diverse genetic backgrounds
11aS)-7-hydroxy-9a
ultrasonic and warming and heat to 80°C)
LDN193189 or vehicle is applied to mice 5 days post-tumor cell injection before tumors are palpable
InChi: InChI=1S/C25H24N4O2/c1-28(2)12-7-13-29-15-19(17-9-4-6-11-21(17)29)23-22(24(30)27-25(23)31)18-14-26-20-10-5-3-8-16(18)20/h3-6
Ro 25-6981 maleate Catalog No.:M9288-2 ROC-325 exhibited superior in vitroRo 25 6981 is a highly potent and selective blocker of N methyl D aspartate receptors containing the NR2B subunit. Ro 25 6981 inhibited 3H MK 801 binding to rat forebrain membranes in a biphasic manner with IC50 values of 0. 003 microM and 149 microM for high (about 60%) and low affinity sites, respectively. NMDA receptor subtypes expressed in Xenopus oocytes were blocked with IC50 values of 0. 009 microM and 52 microM for the subunit combinations
US$ 193.00
US$ 142.00
US$ 138.00
US$ 420.00
US$ 192.00
US$ 154.00
US$ 132.05
US$ 172.00
US$ 65.55
US$ 86.00